A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex ...
Sources familiar with operations at the USPTO have told IPWatchdog that USPTO Director John Squires has informed the PTAB ...
Ad Policy President Donald Trump and Mehmet Oz listen to Chief Design Officer of the National Design Studio Joe Gebbia ...
Congress should let provisional applications be renewable for an extra year, and then publish them if a nonprovisional is not ...
Basic research needs to be a federal priority if we're going to keep feeding innovations that later can produce the SpaceXes of the world," Joseph Jewell said.
To get drugs and devices out faster, the FDA lets companies conduct studies of safety or efficacy after the products are ...
Weight loss comparable to semaglutide: In obese mice fed a high-fat diet, ART27.13 as a monotherapy reduced body weight from baseline by approximately 20% over four weeks – essentially mirroring the ...
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was ...
Webcast: Anticipating and Resolving Potential Licensing and Collaboration Disputes Before They Arise
Join Gibson Dunn lawyers for the first recorded session of a three-part series following a single life sciences collaboration ...
Forty years after its founding, Summit Brewing Co. is headed for foreclosure, spelling uncertainty for one of Minnesota's ...
The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Ehud Geller, Executive Chairman and ...
An analysis of FDA data found hundreds of postmarket studies running behind schedule, raising questions about the agency’s ability to ensure manufacturers follow through.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results